Pillar Biosciences Closes $29.7 Million in Series C Financing
05/12/20, 3:08 PM
Location
Money raised
$29 million
Round Type
series c
Pillar Biosciences, an NGS clinical cancer diagnostics company, today announced the closing of a $29.7 million Series C preferred stock financing. The financing will accelerate the expansion of Pillar's in vitro diagnostic and research use only panels and advance Pillar's global commercial outreach.
Company Info
Company
Pillar Biosciences
Location
natick, massachusetts, united states
Additional Info
Pillar Biosciences is a clinical cancer diagnostics company based in Boston, Massachusetts and Shanghai, China. Our automatable variant detection technologies deliver robust results with rapid turnaround times through streamlined NGS workflows. Our SLIMamp®- and PiVAT®-based products help high-throughput reference laboratories and clinical oncology laboratories make precision medicine practical by boosting their diagnostic productivity. Learn more at https://pillar-biosciences.com.